Jane is a Partner in the corporate and commercial division. She specialises in helping and supporting clients with the management and resolution of commercial disputes. Jane is a member of the Healthcare Infrastructure Projects team and the Procurement team at Capsticks.
Jane has been developing her expertise for over 20 years. Jane and her team ensure that disputes, when they arise, are managed responsively, effectively, and by the people with the right skills/experience. They understand the context of the dispute and the need to deliver value for money and they make clear recommendations to help clients move forward. Jane is adept at guiding her clients through all kinds of dispute resolution processes, from negotiated settlement to High Court trials.
- Providing advice on numerous issues connected with the coronavirus pandemic including advice on abandonment of procurements, breaches/termination of contracts, intellectual property rights, insolvency, extension of contracts without running a tender, reputation management, debt recovery and fraud.
- Successfully defending an NHS Trust against a procurement challenge relating to managed pathology services, including obtaining the challenger’s consent to an application to lift the automatic suspension of the contract award and establishing/complying with a confidentiality ring.
- Successfully defending a group of clients from a procurement challenge relating to NHS 111 and urgent care services and preparing the evidence to support an application to lift the automatic suspension of the contract award.
- Assisting an NHS Trust and the Department of Health and Social Care with the aftermath of the collapse of a construction contractor in a PF2 scheme, leading to the termination of that scheme.
- Recovering sums lost through fraud by contractors and by primary care practitioners.
- Brokering the settlement, at mediation, of a high value contractual dispute between an NHS Trust and the contractor responsible for FM.
- Working with the Department of Health and Social Care in litigation involving pharmaceutical companies who are alleged to have undertaken anti-competitive behaviour and artificially inflated the price of drugs/products.
- LLB Law - University of Hull